Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
SRU Biosystems Secures Exclusive License to Evanescent Resonance Technology for Optimized Drug Discovery and Diagnostics
April 10th, 2007
SRU Biosystems, a leader in highly sensitive labeled and label-free detection technologies, announced that it has secured an exclusive license to Evanescent Resonance (ER) technology, a detection platform that enhances the sensitivity of fluorescence-based assays for drug discovery and diagnostics. Novartis has granted SRU the exclusive rights to the ER technology for use in drug discovery, as well as all supporting intellectual property rights. The sensitivity of ER technology should make it possible to profile the entire genome utilizing minute samples, or to perform ultra-sensitive ELISAs. "The addition of ER technology to our portfolio means that SRU has the most...
Source: Drug Law Weekly (2007-04-10)
|
